NCT04822337 2026-04-16
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
Wake Forest University Health Sciences
Phase 1/2 Active not recruiting
Clinical Trials
10 trialsNCT04973605 2026-04-16
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
BeOne Medicines
Phase 1/2 Recruiting
NCT05434689 2026-04-15
COMMANDER
University of Alabama at Birmingham
Phase 1/2 Active not recruiting
NCT07463807 2026-04-13
Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment
National Cancer Institute (NCI)
Phase 1/2 Not yet recruiting
NCT01297764 2026-03-23
QUAD
Hackensack Meridian Health
Phase 1/2 Active not recruiting
NCT07479979 2026-03-23
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
Hoosier Cancer Research Network
Phase 1/2 Not yet recruiting
NCT02773030 2026-03-20
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
Celgene
Phase 1/2 Active not recruiting
NCT04764942 2026-02-25
Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial
Mayo Clinic
Phase 1/2 Active not recruiting
NCT05199311 2026-02-18
Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma
Hackensack Meridian Health
Phase 1/2 Recruiting
NCT06892522 2026-02-17
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
AbbVie
Phase 1/2 Recruiting